Envista Holdings Corporation
$4.62B- Market cap
- $4.38B
- Debt
- +$1.45B
- Cash
- −$1.21B
Capital structure 75% equity / 25% debt · EV / Revenue 1.70x · EV / EBITDA 12.35x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NVST stock price vs ARCT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ARCT's multiple
Needs ARCT P/E.
Implied fair value · at NVST's multiple
Needs EPS (TTM) is negative, NVST P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: NVST FY 2025 (ended Dec 31, 2025) · ARCT FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 75% equity / 25% debt · EV / Revenue 1.70x · EV / EBITDA 12.35x
Capital structure 90% equity / 10% debt · EV / Revenue 3.30x
NVST carries the larger enterprise value at $4.62B against $270.74M; NVST trades on the lower EV / Revenue multiple (1.70x vs 3.30x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ENVISTA HOLDINGS CORPORATION · implied price per share
Bear
$13.25
Base
$15.82
Bull
$19.19
ARCTURUS THERAPEUTICS HOLDINGS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.47x
0.24x
Net debt / EBITDA
Leverage against operating earnings
0.63x
2.72x
Cash and equivalents
Liquid reserves on the balance sheet
$1.21B
$230.91M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ALIGN TECHNOLOGY INC
NVST vs ALGN
HENRY SCHEIN INC
NVST vs HSIC
PATTERSON COMPANIES, INC.
NVST vs PDCO
DENTSPLY SIRONA Inc.
NVST vs XRAY
Moderna, Inc.
NVST vs MRNA
BioNTech SE
NVST vs BNTX
ALNYLAM PHARMACEUTICALS, INC.
NVST vs ALNY
Sarepta Therapeutics, Inc.
NVST vs SRPT
Intellia Therapeutics, Inc.
NVST vs NTLA
$1.45B
$52.00M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.